Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia

Background: For heart failure with reduced ejection fraction (HFrEF), suboptimal use of renin-angiotensin-aldosterone system inhibitors (RAASis), including mineralocorticoid receptor antagonists (MRAs), due to hyperkalemia, may be improved by potassium binders. Objectives: This prespecified analysis...

Descripción completa

Detalles Bibliográficos
Autores: Coats, Andrew Justin Stewart|||0000-0002-2771-4260, Anker, Stefan|||0000-0002-0805-8683, Lund, Lars H.|||0000-0003-1411-4482, Filippatos, Gerasimos|||0000-0002-5640-0332, Rossignol, Patrick, Pitt, Bertram, Weir, Matthew R., Kosiborod, Mikhail N.|||0000-0002-3750-9789, Metra, Marco|||0000-0001-6691-8568, Böhm, Michael, Ezekowitz, Justin A.|||0000-0002-2724-4086, Bayés-Genís, Antoni|||0000-0002-3044-197X, Mentz, Robert J., Ponikowski, Piotr|||0000-0002-3391-7064, Senni, Michele|||0000-0001-5502-7882, Cleland, John G. F., Goudev, Assen, Khintibidze, Irakli, Lindenfeld, JoAnn|||0000-0001-9207-3634, Merkely, Bela|||0000-0001-6514-0723, Waechter, Sandra, Budden, Jjeffrey, Perrin, Amandine, Butler, Javed|||0000-0001-7683-4720
Tipo de recurso: artículo
Fecha de publicación:2024
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:310576
Acceso en línea:https://ddd.uab.cat/record/310576
https://dx.doi.org/urn:doi:10.1016/j.jchf.2024.08.003
Access Level:acceso abierto
Palabra clave:Heart failure with reduced ejection fraction
Hyperkalemia
Patiromer
Potassium binder
Renin-angiotensin-aldosterone system inhibitor
Descripción
Sumario:Background: For heart failure with reduced ejection fraction (HFrEF), suboptimal use of renin-angiotensin-aldosterone system inhibitors (RAASis), including mineralocorticoid receptor antagonists (MRAs), due to hyperkalemia, may be improved by potassium binders. Objectives: This prespecified analysis of the phase 3 DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) trial assessed the effect of patiromer in patients with HFrEF and either current or past hyperkalemia. Methods: Patients with HFrEF and current or past (within 1 year before enrollment) hyperkalemia (serum potassium [sK].

Similares en LA Referencia